How is Zepbound dosed?
The prescribing information’s own escalation schedule, the trials it cites, its boxed warning and adverse-event table, and how research-grade tirzepatide relates to the branded product — every figure attributed to where it was read.
Topic: Reading Zepbound’s FDA prescribing information
Audience: Anyone comparing a dosing schedule against its source
Reading time: 7–9 minutes
Not affiliated with Eli Lilly. Prof. Peptide is not affiliated with, endorsed by, or sponsored by Eli Lilly. Zepbound is a registered trademark of Eli Lilly and Company. This page reports what Eli Lilly’s own prescribing information and FDA’s own publications state; it does not sell, ship, or recommend the branded product.
On this page
What Zepbound is
Zepbound is a brand name. Its active ingredient is tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The label states Zepbound is indicated, in combination with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity, in combination with weight reduction. Zepbound’s label does not require or address a type 2 diabetes diagnosis.
Tirzepatide is also sold under a separate brand name, at different doses, for a different indication — Mounjaro (type 2 diabetes) is the same molecule with a different label. The Prof. Peptide tirzepatide profile covers how the two relate, the mechanism, and the published trial evidence across both. This page reads Zepbound’s own label specifically, since its dosing schedule, indications, and cited trials are not identical to Mounjaro’s.
What the label specifies
The table below is Zepbound’s recommended dosage as stated in sections 2.1 and 2.2 of its prescribing information — Eli Lilly, ZEPBOUND (tirzepatide) injection prescribing information, DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective August 28, 2026.
| Step | Dosage | As specified by the label |
|---|---|---|
| Initiation | 2.5 mg once weekly | For 4 weeks. The label states this dosage is for treatment initiation and is not approved as a maintenance dosage. |
| First increase | 5 mg once weekly | After 4 weeks on the 2.5 mg dosage. |
| Further increases (if needed) | +2.5 mg increments | After at least 4 weeks on the current dose, until the maintenance dosage is reached. |
| Maintenance — weight reduction | 5 mg, 10 mg, or 15 mg once weekly | The label states to consider treatment response and tolerability when selecting the maintenance dosage. |
| Maintenance — obstructive sleep apnea | 10 mg or 15 mg once weekly | The label states to consider treatment response and tolerability when selecting the maintenance dosage. |
| Maximum dosage | 15 mg once weekly | For all approved indications. |
Section 2.3 states that if a dose is missed, the label instructs administering Zepbound as soon as possible within 4 days (96 hours) of the missed dose; if more than 4 days have passed, the label instructs skipping the missed dose and resuming the regular weekly schedule — the same window stated on Mounjaro’s label, since both share the same molecule and manufacturer.
Dosage forms and strengths (section 3) list four separate presentations at the same 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per-injection strengths: single-dose pens, single-dose vials, multi-dose vials, and single-patient-use KwikPens. The multi-dose vial and KwikPen each hold 4 doses at a higher total concentration than the single-dose forms (for example, the 2.5 mg strength is 10 mg/2.4 mL, 4.17 mg/mL, in the multi-dose vial or KwikPen, versus 2.5 mg/0.5 mL in the single-dose pen or vial) — the per-injection dose is identical across all four forms; only the container and total volume differ.
The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.
What the trials administered
Section 14 of the label (Clinical Studies) names Zepbound’s trials as “Study 1” through “Study 5,” each with its own NCT registry number — the label never uses the word “SURMOUNT” (confirmed by a direct search of the label text, zero hits). “SURMOUNT” is the separately-published, publicly known name for this trial program; the citation below follows the label’s own naming. The two trials below are the ones underlying the primary weight-reduction dosing and outcomes discussed on this page. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when a marker resolves to a named, checkable primary source. Both grade as attributed: each is named in the label itself, with a registry number checkable against ClinicalTrials.gov independent of the label.
Study 1 (NCT04184622)
72-week, randomized, double-blind, placebo-controlled trial
Arms: Placebo (ITT N=643), ZEPBOUND 5 mg (N=630), 10 mg (N=636), 15 mg (N=630) — adults with obesity, or overweight with at least one weight-related comorbid condition, excluding type 2 diabetes
Endpoint reported: Body weight change from baseline at week 72: −3.1% (placebo) vs. −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg); all doses p<0.001 vs. placebo.
Attributed — named and described in full in the label's own Clinical Studies section (14.2), primary source open below.
Study 2 (NCT04657003)
72-week, randomized, double-blind, placebo-controlled trial
Arms: Placebo (ITT N=315), ZEPBOUND 10 mg (N=312), 15 mg (N=311) — adults with BMI ≥27 kg/m² and type 2 diabetes, HbA1c 7–10%
Endpoint reported: Body weight change from baseline at week 72: −3.2% (placebo) vs. −12.8% (10 mg), −14.7% (15 mg); both doses p<0.001 vs. placebo.
Attributed — named and described in full in the label's own Clinical Studies section (14.2), with a registry number checkable against ClinicalTrials.gov independent of the label.
Mounjaro’s label cites a different trial program (the SURPASS trials, for type 2 diabetes) at different indications. Those figures belong to Mounjaro’s own label, not Zepbound’s, even though both products share the same active ingredient — the tirzepatide profile covers the trial evidence across both brands directly.
The label’s warnings and adverse events
Boxed warning: risk of thyroid C-cell tumors
The label states: “In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.”
The label states Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and instructs counseling patients on the potential risk and on symptoms such as a mass in the neck, dysphagia, dyspnea, or persistent hoarseness.
Table 1 of the label reports adverse reaction rates (≥2% and greater than placebo) from Study 1 and Study 2, the weight-reduction and long-term maintenance trials:
| Adverse reaction | Placebo (N=958) | Zepbound 5 mg (N=630) | Zepbound 10 mg (N=948) | Zepbound 15 mg (N=941) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Dyspepsia | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
Compounding and research-grade tirzepatide
Zepbound’s prescribing information does not mention compounding. The word does not appear anywhere in the label. Everything above this section describes a prescription drug product, manufactured by Eli Lilly and dispensed by a pharmacy against a prescription.
Research-grade tirzepatide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded product described above nor a pharmacy-compounded version of it. It is sold labeled for research use, not for human administration, and it is not dispensed against a prescription.
Separately from the branded label, FDA has published its own position on compounded tirzepatide. Its April 1, 2026 statement on compounding, once the national GLP-1 supply stabilized, describes the conditions under which a compounded drug can lawfully be exempt under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, and states FDA’s position that a compounded product is treated as an unlawful copy of a commercially available drug when it shares the same active ingredient, a similar or easily substitutable strength, and the same route of administration — unless a prescriber documents a significant difference for an individual patient.
On April 30, 2026, FDA announced it is proposing to exclude tirzepatide, semaglutide, and liraglutide from the 503B bulks list entirely, stating it “did not identify a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, and liraglutide from bulk drug substances.” The public comment period on that proposal closed; as of this page’s last check, FDA had not published a final determination.
None of this changes what the label above states, and none of it describes Prof. Peptide’s vendors as compounding pharmacies — they are not. It is published here because a reader comparing a branded dosing schedule against a research-grade product should be able to see, in one place, that the two are governed by different rules, and that the regulatory status of compounded tirzepatide is itself unsettled and separate from both.
How this page differs from Mounjaro’s and the tirzepatide profile
Zepbound and Mounjaro share an active ingredient, and largely share the same once-weekly, 2.5 mg-increment escalation mechanics and the same 4-day missed-dose window. What differs is the label built around that molecule. Zepbound’s label covers weight reduction and obstructive sleep apnea in adults without a type 2 diabetes requirement, citing Study 1 through Study 5. Mounjaro’s label is type-2-diabetes-only and cites the SURPASS program exclusively. Zepbound’s boxed warning is worded for studies “in rats,” while Mounjaro’s is worded for studies “in both male and female rats” — a difference in how each label describes its own nonclinical data, not a difference in the underlying molecule.
Zepbound and Wegovy are both weight-reduction labels but different molecules with separate trial programs, separate ADR tables, and separate missed-dose windows (4 days for Zepbound, 2 days for Wegovy injection) — this page and Wegovy’s guide are not restatements of one another; each reads its own label.
The tirzepatide profile is a different kind of page: it covers the molecule’s dual-agonist mechanism and the published trial evidence across both brands at once, without reading either FDA label’s escalation schedule, boxed warning, or adverse-event table in the detail this page does. This page exists because Zepbound’s own prescribing information has figures — the maintenance dosage options by indication, the Study 1 and Study 2 weight-change results, the ADR percentages by dose — that the profile doesn’t report and that only Zepbound’s own label states. For an FDA-approved injectable peptide from a different class entirely — a GHRH analog with its own current label, not a GLP-1/GIP agonist — see how tesamorelin is dosed.
FAQ
Is Zepbound the same as tirzepatide?
What is the starting dose on the Zepbound label?
What is the maximum Zepbound dose?
What happens if a dose is missed?
Does Zepbound carry a boxed warning?
Is compounded or research-grade tirzepatide the same as Zepbound?
References
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information. DailyMed, setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 2026-08-28. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Drug Alerts and Statements, 2026-04-01. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. Press Announcements, 2026-04-30. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1), NCT04184622. https://clinicaltrials.gov/study/NCT04184622
- ClinicalTrials.gov. A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-2), NCT04657003. https://clinicaltrials.gov/study/NCT04657003
We may earn commissions from peptide vendor affiliate links.